Print Page

Letters to Healthcare Providers
 
Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management (Letter to Healthcare Professionals)
 
 
 
Attachment:
  1. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management  
Related Information:
The United Kingdom: Dupilumab (Dupixent▼): risk of ocular adverse reactions and ... Posted 2022-11-30
 
back